Examining the Feasibility of Surgery Omission After Neoadjuvant Systemic Therapy in Invasive Breast Cancer

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses eliminating surgery for select patients with a pCR after neoadjuvant therapy for early breast cancer.

Dr Kuerer discusses the potential to omit surgery in patients with HER2-positive or triple-negative breast cancer who have pCR after neoadjuvant therapy.

Henry Kuerer, MD, PhD, discusses considerations for the selective omission of surgery in HER2-positive breast cancer or triple-negative breast cancer.

No recurrences, disease-free survival events, or deaths were reported in select patients with breast cancer who had surgery omitted.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast cancer.